51³ΙΘΛΆ―Βώ

Meeting Coverage

ASCO Video Pearls: Immunotherapy

Video Pearls from the American Society of Clinical Oncology

Combination of Pembro and Liposomal Gemcitabine Shows Safety in Solid Tumor Patients

Feasibility and dose limiting toxicity findings prompt further investigation into tumor responses

image

Latest ASCO Video Pearls: Immunotherapy Meeting Coverage

Novel IL-2 Agent Shows Promise in Advanced Solid Tumors

WTX-124 demonstrated objective responses post-checkpoint blockade in phase I study

July 2, 2024
What Are the Available Treatments for Non-Clear Cell Kidney Cancer?

Monty Pal, MD, highlights various studies and current treatment approaches

June 25, 2024
Regorafenib-Pembrolizumab Has 'Modest' Activity in HCC Post-Immunotherapy

Study tests second-line option for patients who progressed on immune checkpoint inhibitors

June 18, 2024
Transcriptional Profiling May Improve Outcomes in Young-Onset Colorectal Cancer

Researchers found link to certain pathways that affect immune modulation

July 14, 2023
STRIDE Regimen Shows Manageable Safety in Unresectable Liver Cancer

Immune-mediated toxicities did not preclude an overall survival benefit, Jun Gong reports

July 7, 2023
Vorasidenib for Low-Grade Glioma Doubles Progression-Free Survival

INDIGO demonstrates major treatment advance for patients with IDH1/2-mutant disease

June 30, 2023
Sparing Melanoma Survivors From Overexposure to Surveillance Imaging

Study examined follow-up scans every 6-12 months instead of the standard 3-month interval

June 23, 2023

Latest Oncology/Hematology Meeting Coverage